SEARCH:   Advanced

Blood, 15 October 2007, Vol. 110, No. 8, pp. 3064-3070. Prepublished online as a Blood First Edition Paper on June 14, 2007; DOI 10.1182/blood-2007-04-067215. This Article Full Text (PDF) All Versions of this Article: blood-2007-04-067215v1 110/8/3064    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Brunstein, C. G. Articles by Wagner, J. E Search for Related Content PubMed PubMed Citation Articles by Brunstein, C. G. Articles by Wagner, J. E Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 24, 2007 Accepted June 6, 2007 Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplant outcomes in 110 adults with hematological disease Claudio G. Brunstein*, Juliet N Barker, Daniel J Weisdorf, Todd E DeFor, Jeffrey S Miller, Bruce R Blazar, Philip B. McGlave, and John E Wagner Division of Medical Hematology, Oncology & Transplantation, Blood and Marrow Transplant Program, University of Minnesota Medical School, Minneapolis, MN, United States Division of Pediatric Hematology, Oncology & Transplantation, Blood and Marrow Transplant Program, University of Minnesota Medical School, Minneapolis, MN, United States * Corresponding author; email: bruns072{at}umn.edu. We evaluated the efficacy of UCB in the setting of a nonmyeloablative regimen consisting of fludarabine (200 mg/m2), cyclophosphamide (50 mg/kg) and a single fraction of total body irradiation (200 cGy) with cyclosporine and mycophenolate mofetil for posttransplantation immunoprophylaxis. The target cell dose for the UCB graft was 3.0 x 107 nucleated cells/kg resulting in the selection of a second partially HLA matched UCB unit in 85%. One-hundred and ten patients (median age: 51 years) with hematological disease were enrolled. Neutrophil recovery was achieved in 92% at median of 12 days. Incidences of grades III-IV acute and chronic graft-versus-host disease (GVHD) were 22% and 23%, respectively. Transplant-related mortality was 26% at 3 years. Survival and event-free survival (EFS) at 3 years were 45% and 38%, respectively. Favorable risk factors were absence of high risk clinical features (Karnofsky 50-60, serious organ dysfunction, recent fungal infection, p<0.01) and absence of severe GVHD (p=0.04) for survival, and absence of high risk clinical features ( p<0.01) and use of two UCB units (p=0.07) for EFS. These findings support the use of UCB after a nonmyeloablative conditioning as a strategy for extending the availability of transplant therapy particularly for older patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Are 2 cords better than 1? Elizabeth Shpall, Marcos de Lima, Roy Jones, and Richard Champlin Blood 2007 110: 2789-2790. [Full Text] [PDF] This article has been cited by other articles: D. M. Weinstock, C. Case Jr, J. L. Bader, N. J. Chao, C. N. Coleman, R. J. Hatchett, D. J. Weisdorf, and D. L. Confer Radiologic and nuclear events: contingency planning for hematologists/oncologists Blood, June 15, 2008; 111(12): 5440 - 5445. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020